Next-Generation Sequencing in the Diagnostic Workup of Neonatal Dried Blood Spot Screening in Sweden 2015-2023.
JSON
Sörensen L, Asin-Cayuela J, Barbaro M, Bruhn H, Engvall M, Lesko N, Naess K, Oscarson M, Shen Y, Ueberschär M, Wredenberg A, Sterky FH, Wedell A, Zetterström RH
Int J Neonatal Screen 11 (3) - [2025-09-03; online 2025-09-03]
Sweden has one neonatal screening laboratory and two centers conducting diagnostic workup for inborn errors of metabolism (IEM). Next-generation sequencing (NGS) has been gradually introduced as a confirmatory diagnostic test in the Swedish newborn screening program. Here, we describe the use of NGS in the diagnostic workup of IEM in screening-detected babies in Sweden between 2015 and 2023. During this period, 1,023,344 newborn children were screened, and 81 of 290 IEM cases were genetically confirmed using NGS. Planned improvements to the program are to perform genetic validation directly on the initial dried blood spot (DBS). As whole-genome sequencing (WGS) is superior in detecting causative genetic variants compared to Sanger sequencing, targeted NGS, and whole-exome sequencing (WES), it will likely become the method of choice more broadly in the future. A strong focus is to consolidate the nationally coordinated DBS newborn screening program, with all its individual components, including screening, targeted diagnostics, individualized treatment, and follow-up. This challenges the current regionalized organization of Swedish healthcare, which hinders close national collaboration between experts and sharing of data, as well as equal access to advanced treatments for identified patients, regardless of their place of birth.
Clinical Genomics Stockholm [Service]
PubMed 40981303
DOI 10.3390/ijns11030073
Crossref 10.3390/ijns11030073
pmc: PMC12452496
pii: ijns11030073